Rucaparib Prolongs PFS in Ovarian Cancer

Rucaparib significantly prolongs progression-free survival among patients with BRCA-mutant or BRCA wild-type and high loss of heterozygosity (LOH), recurrent, platinum-sensitive, high-grade ovarian carcinomas, according to a study published in The Lancet Oncology.

Poly ovariancancerrisktreatment_944429(ADP-ribose) polymerase (PARP) inhibitors have demonstrated activity in ovarian carcinomas with homologous recombination deficiency. In addition to BRCA1 and BRCA2 mutations, researchers hypothesized that genomic LOH might also predict response to treatment with PARP inhibitors.

To determine if tumor genomic LOH is associated with response to rucaparib, researchers developed ARIEL2 (ClinicalTrials.gov Identifier: NCT01891344), an international, 2-part, open-label, phase 2 trial. In part 1, investigators enrolled 192 patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma.

Participants were classified into 1 of 3 predefined homologous recombination deficiency subgroups on the basis of tumor mutational analysis: BRCA-mutant (deleterious germline or somatic), BRCA wild-type and LOH high (LOH high group), or BRCA wild-type and LOH low (LOH low group). Patients received rucaparib orally twice daily continuously in 28-day cycles until disease progression or unacceptable toxicity.

Treatment with rucaparib significantly reduced the risk of progression or death by 73% in the BRCA-mutant group (hazard ratio, 0.27; 95% CI, 0.16-0.44; P < .0001) and by 38% in the LOH high subgroup (hazard ratio, 0.62; 95% CI, 0.42-0.90; P = .011) compared with the LOH low subgroup.

Median progression-free survival after rucaparib therapy was 12.8 months (95% CI, 9.0-14.7) in the BRCA-mutant subgroup, 5.7 months (95% CI, 5.3-7.6) in the LOH high subgroup, and 5.2 months (95% CI, 3.6-5.5) in the LOH low subgroup.

The most common grade 3 or worse treatment-emergent adverse events were anemia in 22% of patients, and elevations in alanine aminotransferase or aspartate aminotransferase in 12%. No treatment-related deaths were reported.

To read the full article on Cancer Therapy Advisor, please click here.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s